Maribavir is an oral benzimidazole riboside with potent in vitro activity against
cytomegalovirus (CMV), including some CMV strains resistant to ganciclovir. In a …

The anti-cytomegalovirus (CMV) activity and safety of oral maribavir in CMV-seropositive
allogeneic stem-cell transplant recipients were evaluated in a randomized, double-blind …

RK Avery, FM Marty, L. Strasfeld, I. Lee, A. Arrieta, S. Chou, W. Tatarowicz, S. Villano. Oral
maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant …

Cytomegalovirus (CMV) is a common viral pathogen that influences the outcome of liver
transplantation. In addition to the direct effects of CMV syndrome and tissue-invasive …

Background Available drugs against cytomegalovirus have adverse effects that compromise
their prophylactic use in recipients of allogeneic stem-cell transplants. We assessed the …

Background Maribavir is a benzimidazole riboside with activity against cytomegalovirus
(CMV). The safety and efficacy of maribavir for preemptive treatment of CMV infection in …

Background Cytomegalovirus (CMV) infections that are refractory or resistant (RR) to
available antivirals ([val] ganciclovir, foscarnet, cidofovir) are associated with higher mortality …

We summarize the history of the clinical drug development of maribavir for its use as
prophylaxis in stem-cell transplant recipients. We highlight key aspects in the design and …

Despite remarkable advances in the diagnostic and therapeutic modalities for its
management, cytomegalovirus (CMV) remains one of the most important pathogens …

Until recently, available drugs for cytomegalovirus (CMV) prevention and treatment in
transplant patients included (val) ganciclovir, foscarnet, and cidofovir. Use of these drugs is …